Ramucirumab as Second-Line Therapy in Metastatic Gastric Cancer: Real-World Data from the RAMoss Study

Overview of attention for article published in Targeted Oncology, March 2018

Altmetric Badge

About this Attention Score

So far, Altmetric has seen 3 X posts from 3 X users, with an upper bound of 1,616 followers.

RT @TargetOncology: Ramucirumab as Second-Line Therapy in Metastatic Gastric Cancer: Real-World Data from the RAMoss Study https://t.co/ebK…

RT @TargetOncology: Ramucirumab as Second-Line Therapy in Metastatic Gastric Cancer: Real-World Data from the RAMoss Study https://t.co/ebK…

Ramucirumab as Second-Line Therapy in Metastatic Gastric Cancer: Real-World Data from the RAMoss Study https://t.co/ebKe3qMFPb